U.S. regulators say GlaxoSmithKline’s antibody drug should no longer be used because it is likely ineffective against the new Omicron subvariant.

https://t.co/qaV3jAItUN
U.S. pulls GlaxoSmithKline's COVID-19 drug as BA.2 Omicron dominates new cases